Targeted drug delivery via human epidermal growth factor receptor for sustained release of allyl isothiocyanate

David Encinas-Basurto, Josué Juarez, Miguel A. Valdez, María G. Burboa, Silvia Barbosa, Pablo Taboada*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

14 Citas (Scopus)


In this study, allyl-isothiocyanate (AITC)-loaded Polylactic-Co-Glycolic Acid (PLGA) Nanoparticles (NPs) were prepared for targeting epithelial squamous carcinoma cells using a specific antibody targeting the Epidermal Growth Factor (EGF) receptor overexpressed on the cell membranes. AITC-loaded PLGA NPs showed more effective anticancer properties compared with free AITC, and their cytotoxicity was even more pronounced when the anti-EGFR antibody was covalently attached to the NPs surface. This targeting ability was additionally tested by co-culturing cervical HeLa cells, with very few EGFR on the membranes, and epithelial squamous carcinoma A431 cells, which largely overexpressed EFGR, being observed the specific localization of the antibody-functionalized AITC-loaded PLGA NPs solely in the latter types of cells, whereas non-functionalized NPs were distributed randomly in both cell types in much lesser extents. Thus, our findings support the development of drug delivery strategies that enhances the delivery of anti-cancer natural compounds to tumor tissue, in this case, by targeting specific tumor cell receptors with cell-specific ligands followed by tumor sensitization.

Idioma originalInglés
Páginas (desde-hasta)1252-1260
Número de páginas9
PublicaciónCurrent topics in medicinal chemistry
EstadoPublicada - 2018

Nota bibliográfica

Publisher Copyright:
© 2018 Bentham Science Publishers.


Profundice en los temas de investigación de 'Targeted drug delivery via human epidermal growth factor receptor for sustained release of allyl isothiocyanate'. En conjunto forman una huella única.

Citar esto